Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Cyclerion Therapeutics (CYCN) Shares Outstanding (Weighted Average) (2019 - 2025)

Cyclerion Therapeutics has reported Shares Outstanding (Weighted Average) over the past 7 years, most recently at $3.0 million for Q3 2025.

  • Quarterly results put Shares Outstanding (Weighted Average) at $3.0 million for Q3 2025, up 18.37% from a year ago — trailing twelve months through Sep 2025 was $3.0 million (up 18.37% YoY), and the annual figure for FY2024 was $2.5 million, up 7.7%.
  • Shares Outstanding (Weighted Average) for Q3 2025 was $3.0 million at Cyclerion Therapeutics, up from $2.8 million in the prior quarter.
  • Over the last five years, Shares Outstanding (Weighted Average) for CYCN hit a ceiling of $43.3 million in Q3 2021 and a floor of $43425.0 in Q1 2022.
  • Median Shares Outstanding (Weighted Average) over the past 5 years was $2.5 million (2024), compared with a mean of $9.8 million.
  • Biggest five-year swings in Shares Outstanding (Weighted Average): crashed 99.87% in 2022 and later surged 4910.94% in 2023.
  • Cyclerion Therapeutics' Shares Outstanding (Weighted Average) stood at $39.1 million in 2021, then tumbled by 94.45% to $2.2 million in 2022, then rose by 7.59% to $2.3 million in 2023, then rose by 7.7% to $2.5 million in 2024, then increased by 17.99% to $3.0 million in 2025.
  • The last three reported values for Shares Outstanding (Weighted Average) were $3.0 million (Q3 2025), $2.8 million (Q2 2025), and $2.6 million (Q1 2025) per Business Quant data.